Goldman Sachs
RCEL icon

Goldman Sachs’s Avita Medical RCEL Stock Holding History

Goldman Sachs’s Portfolio RCEL Stock Details RCEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$369K Buy
99,845
+19,232
+24% +$80.7K ﹤0.01% 5777
2025
Q4 		$278K Sell
80,613
-36,232
-31% -$145K ﹤0.01% 5902
2025
Q3 		$597K Buy
116,845
+23,190
+25% +$121K ﹤0.01% 5401
2025
Q2 		$495K Sell
93,655
-73,384
-44% -$534K ﹤0.01% 5164
2025
Q1 		$1.36M Sell
167,039
-8,440
-5% -$78.9K ﹤0.01% 4464
2024
Q4 		$2.25M Buy
175,479
+90,162
+106% +$1.06M ﹤0.01% 4175
2024
Q3 		$915K Sell
85,317
-8,189
-9% -$76.9K ﹤0.01% 4695
2024
Q2 		$741K Buy
93,506
+12,601
+16% +$120K ﹤0.01% 4603
2024
Q1 		$1.3M Buy
80,905
+53,137
+191% +$860K ﹤0.01% 4165
2023
Q4 		$381K Buy
27,768
+5,254
+23% +$60.2K ﹤0.01% 4886
2023
Q3 		$329K Sell
22,514
-10,173
-31% -$172K ﹤0.01% 4851
2023
Q2 		$556K Sell
32,687
-44,108
-57% -$647K ﹤0.01% 4689
2023
Q1 		$1.07M Buy
+76,795
New +$817K ﹤0.01% 4336
2022
Q3 		– Sell
-18,273
Closed -$87K – 6492
2022
Q2 		$87K Sell
18,273
-6,718
-27% -$41.5K ﹤0.01% 5906
2022
Q1 		$212K Sell
24,991
-56,589
-69% -$522K ﹤0.01% 5851
2021
Q4 		$978K Buy
81,580
+71,115
+680% +$1.08M ﹤0.01% 4855
2021
Q3 		$185K Sell
10,465
-134,608
-93% -$2.54M ﹤0.01% 5751
2021
Q2 		$2.98M Buy
145,073
+46,495
+47% +$916K ﹤0.01% 3834
2021
Q1 		$1.95M Buy
+98,578
New +$2.29M ﹤0.01% 4009

Other funds holding RCEL

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DSCM
Divisadero Street Capital Management Miami, Florida $2.39B AUM 134.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Goldman Sachs's RCEL Position: Q1 2026 in Review

Goldman Sachs increased its Avita Medical (RCEL) stake by 24% in Q1 2026, buying an estimated $80.7K and bringing the position to 99,845 shares worth $369K. The position accounts for ﹤0.01% of the portfolio, ranked #5777.

Goldman Sachs first reported a position in RCEL in Q1 2021 and has held it in 19 quarters since. The position peaked at $2.98M in Q2 2021. 79 funds tracked by Wall St. Rank hold RCEL as of Q1 2026.

  • Goldman Sachs held 99,845 shares of Avita Medical worth $369K as of Q1 2026.
  • Goldman Sachs bought 19,232 Avita Medical shares in Q1 2026, an estimated $80.7K.
  • Avita Medical made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #5777 holding.
  • Goldman Sachs first reported a position in Avita Medical in Q1 2021 and has held it in 19 quarters since.
  • Goldman Sachs's Avita Medical position peaked at $2.98M in Q2 2021.
  • 79 funds tracked by Wall St. Rank held Avita Medical as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.